Chugai Pharmaceutical Co., Ltd.
Notice on Discontinuation of GYM329 (emugrobart) Obesity Development, License Return and Resumption of SMA Development
Announced discontinuation of emugrobart obesity development and return of license. Began preparations to resume development in the SMA area. No impact on consolidated earnings forecasts for the fiscal year ending December 2026.
Key Figures
- Financial indicators expected to be affected: Unknown
- Preparations to resume SMA development: In progress
- Phase II interim analysis results for obesity: Failure to meet endpoints; decision to discontinue
AI要約
Key Points
Chugai Pharmaceutical Co., Ltd. announced it will discontinue the obesity development of GYM329 emugrobart and return full licensing rights to Roche. At the same time, based on accumulated safety and pharmacodynamic data and the Phase III design, the company intends to internally advance preparations to resume development for SMA. Following the interim analysis results of the Phase II obesity trial, it was judged that clinically meaningful weight loss could not be achieved. There is no impact on the full-year forecast announced on January 29, 2026.
Outlook and Impact
With a view to resuming emugrobart development for SMA and FSHD, preparations have begun that also consider out-licensing to third parties. The company will evaluate the potential to provide SMA patients with a new treatment option and will consider future development policy. At this time, no impact on consolidated earnings forecasts for the fiscal year ending December 2026 has been confirmed.
Chugai Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
